Epygenix Therapeutics Receives Orphan Medicinal Product Designation in Europe With EPX-200 for the Treatment of Patients With Dravet Syndrome ...Middle East

PARAMUS, N.J., Aug. 2, 2021 /PRNewswire/ -- Epygenix Therapeutics, Inc., a clinical stage biopharmaceutical company focused on rare and intractable genetic epilepsy announced today that the European Medicines Agency (EMA) granted Orphan Medicinal Product Designation to EPX-200 for the...

Hence then, the article about epygenix therapeutics receives orphan medicinal product designation in europe with epx 200 for the treatment of patients with dravet syndrome was published today ( Monday 02/08/2021 - 08:00 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Epygenix Therapeutics Receives Orphan Medicinal Product Designation in Europe With EPX-200 for the Treatment of Patients With Dravet Syndrome )

Also on site :

• Natural gas line rupture stops traffic on 5 Freeway in Castaic
• 30–35 terrorists on radar: Army steps up counterterror ops in J&K; intense vigil amid 'Chillai Kalan'
• No. 20 Virginia notches first 11-win season by beating 25th-ranked Missouri in the Gator Bowl